Akari Therapeutics (AKTX)
NASDAQ:AKTX
Holding AKTX?
Track your performance easily

Akari Therapeutics (AKTX) Income Statement

276 Followers

Akari Therapeutics Income Statement

Last quarter (Q2 2024), Akari Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Akari Therapeutics's net income was $-7.56M. See Akari Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 17.66M$ 16.81M$ 23.23M$ 17.24M$ 18.00M$ 16.98M
Operating Income
$ -19.25M$ -16.81M$ -23.23M$ -17.24M$ -18.00M$ -16.98M
Net Non Operating Interest Income Expense
$ -43.05K$ 82.00K$ 45.94K$ 10.60K$ 13.62K$ 5.53K
Other Income Expense
$ -363.78K$ -6.58M$ -4.98M-$ -556.81K$ -198.95K
Pretax Income
$ -18.85M$ -10.01M$ -17.75M$ -17.42M$ -17.78M$ -16.85M
Tax Provision
--$ -4.20K$ -60.37K-$ -325.18K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -18.80M$ -10.01M$ -17.75M$ -17.42M$ -17.78M$ -16.85M
Basic EPS
$ -1.74-----
Diluted EPS
$ -1.74$ -2.05--$ -0.20$ -0.20
Basic Average Shares
$ 32.35B$ 9.79B$ 312.17M$ 214.61M$ 157.95M$ 91.55M
Diluted Average Shares
$ 32.35B$ 9.79B$ 312.17M$ 214.61M$ 157.95M$ 91.55M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 17.66M$ 16.81M$ 23.23M$ 17.24M$ 18.00M$ 16.98M
Net Income From Continuing And Discontinued Operation
$ -18.80M$ -10.01M$ -17.75M$ -17.42M$ -17.78M$ -16.85M
Normalized Income
$ -14.29M$ -7.91M----
Interest Expense
------
EBIT
$ -18.89M$ -10.01M$ -17.75M$ -17.21M$ -17.98M$ -16.85M
EBITDA
$ -18.88M$ -10.00M$ -17.74M$ -17.21M$ -17.97M$ -16.83M
Currency in USD

Akari Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis